Author: Roy, Vicky; Fischinger, Stephanie; Atyeo, Caroline; Slein, Matthew; Loos, Carolin; Balazs, Alejandro; Luedemann, Corinne; Astudillo, Michael Gerino; Yang, Diane; Wesemann, Duane; Charles, Richelle; Lafrate, A. John; Feldman, Jared; Hauser, Blake; Caradonna, Tim; Miller, Tyler E.; Murali, Mandakolathur R.; Baden, Lindsey; Nilles, Eric; Ryan, Edward; Lauffenburger, Douglas; Beltran, Wilfredo Garcia; Alter, Galit; Alter, Galit
Title: SARS-CoV-2-specific ELISA development Cord-id: wlwh1w5j Document date: 2020_8_8
ID: wlwh1w5j
Snippet: Critical to managing the spread of COVID-19 is the ability to diagnose infection and define the acquired immune response across the population. While genomic tests for the novel Several Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) detect the presence of viral RNA for a limited time frame, when the virus is shed in the upper respiratory tract, tests able to define exposure and infection beyond this short window of detectable viral replication are urgently needed. Following infection, ant
Document: Critical to managing the spread of COVID-19 is the ability to diagnose infection and define the acquired immune response across the population. While genomic tests for the novel Several Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) detect the presence of viral RNA for a limited time frame, when the virus is shed in the upper respiratory tract, tests able to define exposure and infection beyond this short window of detectable viral replication are urgently needed. Following infection, antibodies are generated within days, providing a durable read-out and archive of exposure and infection. Several antibody tests have emerged to diagnose SARS-CoV-2. Here we report on a qualified quantitative ELISA assay that displays all the necessary characteristics for high-throughput sample analysis. Collectively, this test offers a quantitative opportunity to define both exposure and levels of immunity to SARS-CoV-2.
Search related documents:
Co phrase search for related documents- absence presence and actual number: 1
- absence presence and acute syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- absence presence and acutely infected: 1
- absence presence and additional insight: 1
- absence presence and low medium: 1, 2, 3
- absence presence and low medium high: 1, 2
- absence presence and low middle: 1, 2, 3
- absence presence and low sample: 1
- absence presence and magnetic bead: 1, 2, 3
- absolutely key and acute syndrome: 1
- acid testing and acute syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
Co phrase search for related documents, hyperlinks ordered by date